Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Sangamo Therapeutics (SGMO) Receivables Refunds (2023 - 2025)

Sangamo Therapeutics has reported Receivables Refunds over the past 3 years, most recently at $10.1 million for Q4 2025.

  • Quarterly results put Receivables Refunds at $10.1 million for Q4 2025, up 149.07% from a year ago — trailing twelve months through Dec 2025 was $10.1 million (up 149.07% YoY), and the annual figure for FY2025 was $10.1 million, up 149.07%.
  • Receivables Refunds for Q4 2025 was $10.1 million at Sangamo Therapeutics, up from $4.6 million in the prior quarter.
  • Over the last five years, Receivables Refunds for SGMO hit a ceiling of $10.1 million in Q4 2025 and a floor of $3.1 million in Q4 2023.
  • Median Receivables Refunds over the past 3 years was $4.4 million (2025), compared with a mean of $5.1 million.
  • Biggest five-year swings in Receivables Refunds: increased 29.52% in 2024 and later surged 149.07% in 2025.
  • Sangamo Therapeutics' Receivables Refunds stood at $3.1 million in 2023, then increased by 29.52% to $4.1 million in 2024, then surged by 149.07% to $10.1 million in 2025.
  • The last three reported values for Receivables Refunds were $10.1 million (Q4 2025), $4.6 million (Q3 2025), and $4.6 million (Q2 2025) per Business Quant data.